Nova Tina Susan
SEC-identified person · CIK 1302605 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Aurinia Pharmaceuticals Inc. AUPH | Director | filed 2025 - 2026 |
| Brooks Automation, Inc. BRKS | Director | filed 2023 - 2026 |
| Exagen INC. XGN | Director · Executive Chairperson | filed 2019 - 2025 |
| Arena Pharmaceuticals INC ARNA | Director | filed 2006 - 2022 |
| Veracyte, INC. VCYT | Director · President, CLIA U.S. | filed 2015 - 2022 |
| Opgen INC OPGN,OPGNW | Director | filed 2017 - 2019 |
| Nanostring Technologies Inc NSTG | Director | filed 2014 - 2014 |
| DMK Pharmaceuticals Corp DMK | Director | filed 2011 - 2013 |
| Genoptix INC GXDX | Director · President and CEO | filed 2007 - 2011 |
| Cypress Bioscience INC CYPB | Director | filed 2007 - 2010 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.